MedPath

iver toxicity of azathioprine and 6-mercaptopurine in IBD patients.

Phase 4
Recruiting
Conditions
Nodular regenerative hyperplasia
non cirrhotic portal hypertension
10017969
Registration Number
NL-OMON31453
Lead Sponsor
Academisch Ziekenhuis Maastricht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
120
Inclusion Criteria

IBD patients
18 years or older
who have been treated at least 5 years with azathioprine and/or 6-mercaptopurine
who give permission for ultrasound guided liverbiopsy and MRI

Exclusion Criteria

anaemia (Hb < 6.5 mmol/L), thrombocytopenia (Thr < 50 * 10 9/L), prolonged INR (INR > 1.5), ascites.
exclusioncriteria for MRI: pacemaker, ICD, metal intracerebral clips, known allergy for contrast agents that are used, claustrophobia.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath